Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) on Monday, soared 11.34% from the previous trading day, before settling in for the closing price of $4.76. Within the past 52 weeks, AMLX’s price has moved between $1.58 and $19.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 2300.59%. The company achieved an average annual earnings per share of -718.10%. With a float of $43.24 million, this company’s outstanding shares have now reached $67.71 million.
Let’s determine the extent of company efficiency that accounts for 384 employees. In terms of profitability, gross margin is 31.54%, operating margin of -126.88%, and the pretax margin is -131.04%.
Amylyx Pharmaceuticals Inc (AMLX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Amylyx Pharmaceuticals Inc is 36.92%, while institutional ownership is 60.23%. The most recent insider transaction that took place on Sep 30 ’24, was worth 59,429. In this transaction Co-Chief Executive Officer of this company sold 18,589 shares at a rate of $3.20, taking the stock ownership to the 3,120,569 shares. Before that another transaction happened on Sep 30 ’24, when Company’s Co-Chief Executive Officer sold 18,589 for $3.20, making the entire transaction worth $59,414. This insider now owns 3,220,569 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -718.10% per share during the next fiscal year.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Amylyx Pharmaceuticals Inc (AMLX) is currently performing well based on its current performance indicators. A quick ratio of 4.55 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.82, a number that is poised to hit -0.56 in the next quarter and is forecasted to reach -1.88 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Looking closely at Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), its last 5-days average volume was 2.17 million, which is a jump from its year-to-date volume of 2.03 million. As of the previous 9 days, the stock’s Stochastic %D was 13.18%. Additionally, its Average True Range was 0.61.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 65.13%, which indicates a significant increase from 27.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 109.85% in the past 14 days, which was higher than the 88.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.17, while its 200-day Moving Average is $4.34. However, in the short run, Amylyx Pharmaceuticals Inc’s stock first resistance to watch stands at $5.74. Second resistance stands at $6.18. The third major resistance level sits at $6.48. If the price goes on to break the first support level at $5.00, it is likely to go to the next support level at $4.70. Should the price break the second support level, the third support level stands at $4.26.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
Market capitalization of the company is 344.49 million based on 68,548K outstanding shares. Right now, sales total 380,790 K and income totals 49,270 K. The company made 420 K in profit during its latest quarter, and -72,700 K in sales during its previous quarter.
